DelveInsight’s, “Chronic Idiopathic Urticaria Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Idiopathic Urticaria Pipeline landscape. It covers the Chronic Idiopathic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Idiopathic Urticaria therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Chronic Idiopathic Urticaria Pipeline Report

• DelveInsight’s Chronic Idiopathic Urticaria pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Chronic Idiopathic Urticaria treatment.
• The leading companies working in the Chronic Idiopathic Urticaria Market include United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP., Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier, and others.
• Promising Chronic Idiopathic Urticaria Pipeline Therapies in the various stages of development include Omalizumab Injection, Xolair Prefilled Syringe, IGE025, Diphenhydramine, Benralizumab, H1 antihistamines, and others.
• September 2023: Kashiv BioSciences LLC announced a study of phase 3 clinical trials for Omalizumab Injection and Xolair Prefilled Syringe. The purpose of the study is to compare the efficacy, safety, tolerability, and immunogenicity of ADL-018 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment.
• September 2023: Sanofi announced a study of phase 3 clinical trials for Dupilumab SAR231893 and Non Sedating H1-Antihistamine. To demonstrate the efficacy of dupilumab in study participants with CSU who remain symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naïve; Study B: omalizumab intolerant or incomplete responders).

 

Request a sample and discover the recent advances in Chronic Idiopathic Urticaria Treatment Drugs @ Chronic Idiopathic Urticaria Pipeline Report

 

In the Chronic Idiopathic Urticaria pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Idiopathic Urticaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Chronic Idiopathic Urticaria Overview

Chronic Urticaria (CU) conventionally refers to recurrent wheals, on most days of the week, which occur for a period of ≥ six weeks. CU can be further divided into two different subtypes, namely, Chronic Idiopathic Urticaria (CIU) (also called chronic spontaneous urticaria) and chronic inducible urticaria (also called physical urticaria). In most patients, CU is a sporadic and self-limited disorder.

 

Find out more about Chronic Idiopathic Urticaria Therapeutics Assessment @ Chronic Idiopathic Urticaria Preclinical and Discovery Stage Products

 

Chronic Idiopathic Urticaria Emerging Drugs Profile

• Dupilumab: Sanofi
• Barzolvolimab: Celldex Therapeutics
• Lirentelimab: Allakos

 

Chronic Idiopathic Urticaria Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the Chronic Idiopathic Urticaria therapies. The Chronic Idiopathic Urticaria companies which have their Chronic Idiopathic Urticaria drug candidates in the most advanced stage, i.e. phase III include, Sanofi.

 

Learn more about the emerging Chronic Idiopathic Urticaria Pipeline Therapies @ Chronic Idiopathic Urticaria Clinical Trials Assessment

 

Scope of the Chronic Idiopathic Urticaria Pipeline Report

• Coverage- Global
• Chronic Idiopathic Urticaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Idiopathic Urticaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Chronic Idiopathic Urticaria Companies- United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP., Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier, and others.
• Chronic Idiopathic Urticaria Pipeline Therapies- Omalizumab Injection, Xolair Prefilled Syringe, IGE025, Diphenhydramine, Benralizumab, H1 antihistamines, and others.

 

Dive deep into rich insights for new drugs for Chronic Idiopathic Urticaria Treatment, Visit @ Chronic Idiopathic Urticaria Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Idiopathic Urticaria: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Idiopathic Urticaria– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Dupilumab: Sanofi
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Barzolvolimab: Celldex Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Idiopathic Urticaria Key Companies
21. Chronic Idiopathic Urticaria Key Products
22. Chronic Idiopathic Urticaria- Unmet Needs
23. Chronic Idiopathic Urticaria- Market Drivers and Barriers
24. Chronic Idiopathic Urticaria- Future Perspectives and Conclusion
25. Chronic Idiopathic Urticaria Analyst Views
26. Chronic Idiopathic Urticaria Key Companies
27. Appendix

 

For further information on the Chronic Idiopathic Urticaria Pipeline therapeutics, reach out to Chronic Idiopathic Urticaria Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking